glp-1 treatment for newly diagnosed diabetes guidelines Guideline Approach to Therapy in Patients With Type 2 American Association of Clinical Endocrinology

The trial in people with T2D included 281 participants (mean age 56 years, 56% women, mean BMI 35.0 kg/m 2 , mean HbA1c 8.3%) treated with lifestyle only and/or metformin, with similar intervention arms to the obesity trial, albeit retatrutide 0.5 mg rather than 1 mg, and dulaglutide 1.5 mg was an additional comparator [46]

13.5% of participants in the semaglutide group discontinued their treatment due to side effects, compared to 27.6% with liraglutide

But there are some pretty important reasons, like cost savings, minimizing side effects, preventive benefits, or a combination

Theres no mixing, no measuring, no pills to remember

Protein malnutrition, though less common, may occur in patients with severe appetite suppression or food aversions, potentially compromising muscle health and function over time